Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ICSBP CRISPR/Cas9 KO Plasmid (m): sc-421016
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ICSBP CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ICSBP genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ICSBP Antibody (E-9): sc-365042
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ICSBP CRISPR/Cas9 KO Plasmid (m) | sc-421016 | 20 µg | $397.00 |
Overview
Mouse Irf8 encodes the transcription factor ICSBP (interferon consensus sequence-binding protein), a hematopoietic lineage regulator that coordinates myeloid and dendritic cell differentiation and functional maturation. ICSBP integrates interferon-driven transcriptional programs with innate immune signaling to shape antigen presentation, inflammatory cytokine responses, and antimicrobial defense, and it intersects with pathways controlling mononuclear phagocyte development and immune homeostasis. Altered IRF8/ICSBP activity is associated with dysregulated myelopoiesis, impaired dendritic cell function, and aberrant inflammatory states, making it a widely used node for mechanistic studies of immune development and host response.
ICSBP CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Irf8 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Irf8 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Irf8 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ICSBP protein expression.
This CRISPR knockout system enables efficient generation of Irf8-deficient cell models for investigation of ICSBP signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Irf8 exon(s) critical for ICSBP function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Irf8 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ICSBP CRISPR/Cas9 KO Plasmid (m) and ICSBP CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Irf8 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ICSBP HDR Plasmid (m) and ICSBP HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Irf8 homology arms to support homology-directed repair at defined Irf8 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.